AI Summary & Key Takeaways
AI InsightRecurrence occurred at the end of the 16th AZA coursein the third patient and he died after 20 months of the treatment.In elderly patients with AML with a high blast count, the con-tinuation of AZA treatment improves the overall survival rates.
📌 3 Key Takeaways
Abstract
The prognosis of acute myelogenous leukemia (AML) is poor inelderly patients. The mean survival rates at second and fifth yearsfor AML were 10% and 2%, respectively. Here our aim was todemonstrate that the survival rate can be prolonged by long-termazacitidine (AZA) treatment. Complete remission was achievedat the end of the fourth and sixth courses of AZA treatment inthree elderly patients with AML with a high blast count. The firstpatient was followed without any treatment after getting com-plete remission with four courses of AZA, and at the end of 1year follow-up, the patient died due to pneumonia. Complete re-mission was obtained in the second and third patients after fourand six courses of AZA, respectively. Second patient is still beingfollowed up in complete remission at the end of the 20th courseof AZA. Recurrence occurred at the end of the 16th AZA coursein the third patient and he died after 20 months of the treatment.In elderly patients with AML with a high blast count, the con-tinuation of AZA treatment improves the overall survival rates.
Özet
Yaşlı hastalarda akut myeloid löseminin (AML) prognozu kö- tüdür. İki ve 5 yıllık ortalama sağ kalım oranları sırasıyla %10 ve %2’dir. Burada amacımız uzun süreli azasitidin tedavisi ile sağ kalımın uzadığının gösterilmesidir. Yüksek blast sayılı 3 yaşlı AML hastasında 4. Ve 6. Kürler sonunda tam remisyon elde edildi. Birinci olguda 4 kür tedavi ile remisyon elde edil- dikten sonra tedavisiz izlendi. Bir yıl sonunda nüks gelişen hasta pnömoni nedeniyle öldü. İkinci ve 3. olguda sırasıyla 4 ve 6 kür sonunda tam remisyon elde edildi. İkinci olguda 16. Kür sonunda nüks gelişti. Üçüncü olgu ise tedavisinin 16. Ayında halen remisyonda izlenmektedir. Yüksek blast sayılı yaşlı AML hastalarında azasitidin tedavisine devam edilmesi sağ kalım sü- resini artırmaktadır.